Updated recommendations for cholesterol management have been released, advocating for a one-time genetic test for lipoprotein(a) as a strategy to prevent early heart disease. These guidelines, issued jointly by the American Heart Association (AHA) and the American College of Cardiology (ACC) on March 15, 2024, aim to enhance early detection and treatment for cardiovascular issues, which remain the leading cause of death in both men and women in the United States.
Dr. Roger Blumenthal, a cardiologist at Johns Hopkins and chair of the guideline committee, emphasized that more than 80% of cardiovascular events are preventable. Elevated levels of low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are significant contributors to this risk. Dr. Blumenthal noted that relying solely on LDL measurements may not provide a comprehensive understanding of an individual’s risk. Including additional biomarkers, such as lipoprotein(a), allows for a more thorough risk evaluation.
Testing for lipoprotein(a) is a straightforward procedure that is increasingly accessible in primary care settings. Given that its levels are primarily determined by genetics and remain stable throughout a person’s life, the test typically needs to be performed only once, preferably during early adulthood. High levels of lipoprotein(a) can indicate an inherited predisposition to serious cardiovascular complications, including heart attacks and strokes.
Wider Assessment Techniques Recommended
The updated guidelines also advocate for the broader use of coronary calcium scoring, a noninvasive imaging method that quantifies calcified plaque within arteries. Clinicians are encouraged to utilize risk prediction tools, such as PREVENT, which estimates the 10-year and 30-year cardiovascular risk. This information can help guide decisions regarding the initiation of lipid-lowering therapies.
Statins continue to be the primary pharmaceutical option for managing high cholesterol. Under the new guidelines, patients with moderate or relatively low short-term risk may still be considered for early treatment if their overall lifetime risk is deemed elevated. Dr. Steven Nissen, a preventive cardiologist at Cleveland Clinic, described this approach as a fundamental shift in how cardiovascular risk is assessed and treated, emphasizing the importance of a patient’s cumulative risk over their lifetime.
The guidelines predict a significant increase in the number of adults receiving cholesterol-lowering therapy, as generic statins are widely available and can cost as little as $3 per month. Currently, approximately 25% of American adults have high LDL levels, which significantly raises their risk of cardiovascular events.
Emphasis on Lifestyle Changes
In addition to medication, the recommendations highlight the critical role of lifestyle modifications in heart health. Regular exercise, avoiding tobacco, and ensuring adequate sleep are vital components of cardiac prevention. Dr. Leslie Cho, a preventive cardiologist at Cleveland Clinic, reaffirmed that diet and physical activity are foundational to maintaining heart health.
These updated guidelines are documented in the journals Circulation and the Journal of the American College of Cardiology (JACC), and they aim to equip clinicians with more precise tools for managing cardiovascular risk effectively. By promoting earlier intervention and comprehensive risk assessment, the AHA and ACC seek to reduce the incidence of heart disease and improve health outcomes for millions.
